Study summary

The objective of this study is to evaluate the safety and efficacy of ASP1517 compared to darbepoetin alfa in hemodialysis chronic kidney disease patients with anemia.

Additional Study Details

Phase
3
Product
  • roxadustat
  • Darbepoetin alfa
  • Type
    Interventional
    Masking
    Double (Participant, Investigator)
    Enrollment number
    303
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): Japanese

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Republic of Moldova
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Former Serbia and Montenegro
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Republic of Korea
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site JP00035
      Saitama, Saitama, Japan
      Completed
      Site JP00011
      Gunma, Gunma, Japan
      Completed
      Site JP00012
      Nagano, Nagano, Japan
      Completed
      Site JP00004
      Ehime, Ehime, Japan
      Completed
      Site JP00048
      Hokkaido, Hokkaido, Japan
      Completed
      Site JP00058
      Ibaraki, Ibaraki, Japan
      Completed
      Site JP00029
      Kumamoto, Kumamoto, Japan
      Completed
      Site JP00002
      Nagano, Nagano, Japan
      Completed
      Site JP00014
      Fukuoka, Fukuoka, Japan
      Completed
      Site JP00003
      Hokkaido, Hokkaido, Japan
      Completed
      Site JP00045
      Ibaraki, Ibaraki, Japan
      Completed
      Site JP00034
      Niigata, Niigata, Japan
      Completed
      Site JP00047
      Ibaraki, Ibaraki, Japan
      Completed
      Site JP00016
      Saitama, Saitama, Japan
      Completed
      Site JP00026
      Gunma, Gunma, Japan
      Completed
      Site JP00039
      Toyama, Toyama, Japan
      Completed
      Site JP00040
      Aichi, Aichi, Japan
      Completed
      Site JP00008
      Aichi, Aichi, Japan
      Completed
      Site JP00021
      Toyama, Toyama, Japan
      Completed
      Site JP00050
      Gifu, Gifu, Japan
      Completed
      Site JP00013
      Nagasaki, Nagasaki, Japan
      Completed
      Site JP00036
      Okayama, Okayama, Japan
      Completed
      Site JP00043
      Kagoshima, Kagoshima, Japan
      Completed
      Site JP00015
      Osaka, Osaka, Japan
      Completed
      Site JP00051
      Nagano, Nagano, Japan
      Completed
      Site JP00001
      Niigata, Niigata, Japan
      Completed
      Site JP00059
      Fukui, Fukui, Japan
      Completed
      Site JP00030
      Gifu, Gifu, Japan
      Completed
      Site JP00038
      Hokkaido, Hokkaido, Japan
      Completed
      Site JP00020
      Aichi, Aichi, Japan
      Completed
      Site JP00010
      Fukushima, Fukushima, Japan
      Completed
      Site JP00037
      Gunma, Gunma, Japan
      Completed
      Site JP00033
      Aichi, Aichi, Japan
      Completed
      Site JP00005
      Kanagawa, Kanagawa, Japan
      Completed
      Site JP00007
      Osaka, Osaka, Japan
      Completed
      Site JP00024
      Yamagata, Yamagata, Japan
      Completed
      Site JP00044
      Tokushima, Tokushima, Japan
      Completed
      Site JP00056
      Fukushima, Fukushima, Japan
      Completed
      Site JP00018
      Aichi, Aichi, Japan
      Completed
      Site JP00057
      Fukushima, Fukushima, Japan
      Completed
      Site JP00041
      Ibaraki, Ibaraki, Japan
      Completed
      Site JP00046
      Ibaraki, Ibaraki, Japan
      Completed
      Site JP00049
      Fukuoka, Fukuoka, Japan
      Completed
      Site JP00006
      Kyoto, Kyoto, Japan
      Completed
      Site JP00028
      Kumamoto, Kumamoto, Japan
      Completed
      Site JP00055
      Ehime, Ehime, Japan
      Completed
      Site JP00032
      Aichi, Aichi, Japan
      Completed
      Site JP00031
      Hokkaido, Hokkaido, Japan
      Completed
      Site JP00042
      Ibaraki, Ibaraki, Japan
      Completed
      Site JP00052
      Tokyo, Tokyo, Japan
      Completed
      Site JP00027
      Nagano, Nagano, Japan
      Completed
      Site JP00025
      Yamaguchi, Yamaguchi, Japan
      Completed
      Site JP00009
      Fukui, Fukui, Japan
      Completed
      Site JP00053
      Tokyo, Tokyo, Japan
      Completed
      Site JP00054
      Ibaraki, Ibaraki, Japan
      Completed
      Site JP00017
      Ibaraki, Ibaraki, Japan
      Completed
      Site JP00022
      Toyama, Toyama, Japan

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?